LONDON, Feb 16 (Reuters) - Pharmaceuticals group Shire reported a 12 percent rise in full-year earnings afterwhat it said was a transformational year marked by its largestacquisition to date, adding that it is extremely optimistic onlong-term growth prospects.
The London-listed company posted non-GAAP diluted earningsper share of $13.10 on Thursday, right at the top of itsguidance, on revenue up 78 percent to $11.4 billion. (Reporting by Paul Sandle; Editing by David Goodman)